Trial Profile

PETReA: Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Rituximab (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Obinutuzumab; Prednisolone; Vincristine
Indications Follicular lymphoma
Focus Therapeutic Use
Acronyms PETReA

Most Recent Events

01 Aug 2024 Results (n=58) published in the British Journal of Haematology
15 Jun 2023 Results assessing Covid-19 vaccine responses in follicular lymphoma patients presented at the 28th Congress of the European Haematology Association
11 Oct 2022 Planned End Date changed from 1 Dec 2027 to 1 Dec 2029.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com